APA (7th ed.) Citation

Fukuhara, N., Yamamoto, G., Tsujimura, H., Chou, T., Shibayama, H., Yanai, T., . . . Izutsu, K. (2020). Retreatment with brentuximab vedotin in patients with relapsed/refractory classical Hodgkin lymphoma or systemic anaplastic large-cell lymphoma: A multicenter retrospective study. Leukemia & Lymphoma, 61(1), 176. https://doi.org/10.1080/10428194.2019.1654100

Chicago Style (17th ed.) Citation

Fukuhara, Noriko, Go Yamamoto, Hideki Tsujimura, Takaaki Chou, Hirohiko Shibayama, Tomoko Yanai, Kazunori Shibuya, and Koji Izutsu. "Retreatment with Brentuximab Vedotin in Patients with Relapsed/refractory Classical Hodgkin Lymphoma or Systemic Anaplastic Large-cell Lymphoma: A Multicenter Retrospective Study." Leukemia & Lymphoma 61, no. 1 (2020): 176. https://doi.org/10.1080/10428194.2019.1654100.

MLA (9th ed.) Citation

Fukuhara, Noriko, et al. "Retreatment with Brentuximab Vedotin in Patients with Relapsed/refractory Classical Hodgkin Lymphoma or Systemic Anaplastic Large-cell Lymphoma: A Multicenter Retrospective Study." Leukemia & Lymphoma, vol. 61, no. 1, 2020, p. 176, https://doi.org/10.1080/10428194.2019.1654100.